drugset
drugset / Trial / NCT03502018

Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty

NCT03502018 ↗

Phase 4 Completed 50 enrolled Maimonides Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will examine the efficacy of Liposomal Bupivacaine (Exparel) in hip fracture patients undergoing hip hemiarthroplasty for femoral neck fractures through a posterior approach. Post-operative measures will be assessing pain, overall opiate use, delirium, time-to-ambulation and discharge status.

Timeline

Start
2018-03-01
Primary completion
2023-08-31
Completion
2023-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 20 ml Other

Indications

No indication recorded.